Luca has a background in immunology. He is interested in immune-based therapies to treat cancer. As an editor, he mainly handles papers in cancer immunology and immunotherapy.
Maria has a background in physiology and cancer research with a focus on the cell biology and microenvironment aspects. As an editor she mainly handles manuscripts on blood cancer and metabolism, including both basic and clinical studies.
Ilse Ariadna Gutierrez
Ilse has a background in cancer genomics and bioinformatics with a previous focus on leukaemia. As an editor she mainly handles manuscripts on cancer genetics and genomics at the bulk and single-cell levels, and is particularly interested in cancer heterogeneity and evolution.
Stephanie has a background in cancer cell biology with a previous focus on breast cancer, transcriptional factors and kinases. As an editor she mainly handles manuscripts on cancer cell biology and molecular biology.
Ylenia has a background in cancer biology with a focus on cancer stem cells and mechanisms of drug resistance. As an editor she handles translational and clinical studies in cancer as well as cancer stem cells papers.
Paraskevi has a background in cancer biology with a focus on epithelial to mesenchymal transition, cancer stem cells and drug resistance. She also has 4 years of experience from the biotechnology industry in the field of TCR repertoire identification and analysis for immunotherapies. As an editor Paraskevi handles papers on cancer genetics/genomics, epigenetics/epigenomics and immunogenomics.
Katie Ridd (@katieridd)
Katie has a background in cancer cell biology and genetics, and previously focused on skin cancer. As an editor her interests span all of cancer research including clinical, therapy, immunology, metabolism, molecular biology and cell biology. Katie handles an array of papers but has a particular focus on cancer imaging.
Lorenzo has a background in computational epidemiology and innovation complexity. Editorially, he is interested in advancements in digital medicine ethics and safety, in AI studies of consciousness, in real-world-evidence digital medicine, in computational social science and in new developments of data-driven epidemiological models. He handles primarily AI diagnostic and prognostic tools, in silico drug discovery methods and computational epidemiology studies.
Aishwarya has 6+ years of experience in pharmaceutical drug discovery research, spanning multiple therapeutic areas, followed by doctoral studies with a focus on pancreatic cancer. As an editor, she handles broad topics including cancer metastasis, drug discovery, nanotherapy, tumor models and epidemiology.